Trial Profile
Pharmacokinetic exposure of novel oral nano-amorphous sirolimus to the currently used intravenously administered temsirolimus in healthy volunteers: A dose escalation study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 May 2019
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Temsirolimus (Primary)
- Indications Coronary artery restenosis; Fibroma; Kasabach-Merritt syndrome; Lymphangioleiomyomatosis; Renal transplant rejection; Systemic lupus erythematosus
- Focus Pharmacokinetics
- 14 May 2019 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 25 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology